CANTARGIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.488 SEK | -6.11% |
|
+8.56% | +20.06% |
| 05-23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
| 05-21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 84.03M | - | - | - | - | - | |
| 123B | ||||||
| 107B | ||||||
| 24.01B | - | |||||
| 22.59B | - | |||||
| 18.16B |
- Stock Market
- Equities
- CANTA Stock
- Charts Cantargia AB
- Sector Chart